The FDA is warning companies about marketing unapproved eye products
FDA sends letter to pharmacies
The U.S. Food and Drug Administration on Tuesday issued a warning to eight companies, including CVS and Walgreens, about manufacturing or marketing unapproved eye products.The U.S. Food and Drug Administration on Tuesday issued a warning to eight companies, including CVS and Walgreens, about manufacturing or marketing unapproved eye products., the products are illegally marketed to treat conditions like conjunctivitis, cataracts and glaucoma.
The letter said the products could pose an increased risk to users because they can bypass some of the body’s natural defenses., both CVS and Walgreens said they have stopped the sale of the unapproved eye drops, Customers who return the products can get a full refund. The FDA asked the companies to respond within 15 days of receipt of the letters and to lay out the plans they intend to implement to correct the violations.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA warns CVS, Walgreens about marketing of unapproved eye productsThe U.S. Food and Drug Administration this week warned CVS Health Corp. Walgreens Boots Alliance Inc. and several smaller consumer products companies about...
Weiterlesen »
FDA issues warning letter to CVS, Walgreens and others for selling unapproved eye products By ReutersFDA issues warning letter to CVS, Walgreens and others for selling unapproved eye products
Weiterlesen »
FDA warns CVS, others against selling unapproved eye productsThe U.S. Food and Drug Administration on Tuesday warned eight companies, including pharmacy giants CVS Health Corp and Walgreens Boots Alliance , against manufacturing or marketing unapproved eye products.
Weiterlesen »
Here are Tuesday's biggest analyst calls: Nvidia, Tesla, CVS, Oracle, Walmart, Meta, Disney and moreHere are the biggest calls on Wall Street on Tuesday.
Weiterlesen »
4 big analyst picks: CVS picks up upgrade on 'attractive risk/reward,' per Wolfe By Investing.com4 big analyst picks: CVS picks up upgrade on 'attractive risk/reward,' per Wolfe
Weiterlesen »